At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
There are some remissions, but peripheral neuropathy casts a long shadow.
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
With telaglenastat facing a risky trial readout Calithera picks up two bargain-basement oncology projects to pivot to.
Black box warnings could limit the sales of their newly approved therapeutics.
Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.